Shalini Saxena
Overview
Explore the profile of Shalini Saxena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaulding J, Saxena S, Montanari D, Lyon L
ACS Macro Lett
. 2022 May;
2(4):337-340.
PMID: 35581762
Hybrid nanoparticles with complex architectures combine the properties of two distinct materials and integrate them to synergistically provide new characteristics to the assembly. In this work we demonstrate the ability...
2.
Saxena S, Ashwin V, Rajinikanth D
Indian J Otolaryngol Head Neck Surg
. 2019 Nov;
71(Suppl 1):813-815.
PMID: 31742070
Osteomas are benign, slow growing, usually sessile osteogenic tumors of unknown etiology. They arise from proliferation of either cancellous or compact bone. They can be central, peripheral or extra-skeletal based...
3.
Panda S, Saxena S, Guruprasad L
J Biomol Struct Dyn
. 2019 Jun;
38(7):1887-1902.
PMID: 31179839
( is a Gram-negative opportunistic pathogen commonly associated with hospital-acquired infections that are often resistant even to antibiotics. Heptosyltransferase (HEP) belongs to the family of glycosyltransferase-B (GT-B) and plays an...
4.
Mallavarapu B, Abdullah M, Saxena S, Guruprasad L
J Biomol Struct Dyn
. 2018 Sep;
37(14):3751-3763.
PMID: 30239262
Tuberculosis (TB) is a contagious disease caused by or tubercule bacillus, and H37Rv is the most studied clinical strain. The recent development of resistance to existing drugs is a global...
5.
Saxena S, Durgam L, Guruprasad L
J Biomol Struct Dyn
. 2018 May;
37(7):1783-1799.
PMID: 29718775
Development of new antimalarial drugs continues to be of huge importance because of the resistance of malarial parasite towards currently used drugs. Due to the reliance of parasite on glycolysis...
6.
Saxena S, Abdullah M, Sriram D, Guruprasad L
J Biomol Struct Dyn
. 2017 Sep;
36(12):3184-3198.
PMID: 28948866
MurG (Rv2153c) is a key player in the biosynthesis of the peptidoglycan layer in Mycobacterium tuberculosis (Mtb). This work is an attempt to highlight the structural and functional relationship of...
7.
Reshma R, Jeankumar V, Kapoor N, Saxena S, Bobesh K, Vachaspathy A, et al.
Bioorg Med Chem
. 2017 Apr;
25(10):2761-2771.
PMID: 28389113
MTB lysine-ɛ-aminotransferase (LAT) was found to play a crucial role in persistence and antibiotic tolerance. LAT serves as a potential target in the management of latent tuberculosis. In present work...
8.
Samala G, Brindha Devi P, Saxena S, Gunda S, Yogeeswari P, Sriram D
Bioorg Med Chem
. 2016 Sep;
24(21):5556-5564.
PMID: 27667550
Thirty three derivatives of 2-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues were synthesized by molecular modification of a reported antimycobacterial molecule (GSK163574A). Compounds were evaluated in vitro against actively replicative and nutrient starved non-replicative...
9.
Brindha Devi P, Jogula S, Reddy A, Saxena S, Sridevi J, Sriram D, et al.
Mol Inform
. 2016 Aug;
34(2-3):147-59.
PMID: 27490037
Pantothenate synthetase (PS) enzyme involved in the pantothenate biosynthetic pathway is essential for the virulence and persistent growth of Mycobacterium tuberculosis (MTB). It is encoded by the panC gene, and...
10.
Saxena S, Renuka J, Yogeeswari P, Sriram D
Mol Inform
. 2016 Aug;
33(9):597-609.
PMID: 27486079
DNA gyrase of Mycobacterium tuberculosis (MTB) is a type II topoisomerase that ensures the regulation of DNA topology and has been genetically demonstrated to be a bactericidal drug target. Availability...